Article Text

SAT0399 The Patient-Derived PSA Impact of Disease (PSAID) Questionnaire Correlates with Other Outcome Measures: HÜR-BİO REAL Life Results
  1. L. Kilic1,
  2. O. Karadag1,
  3. L. Gossec2,
  4. S. Apras Bilgen1,
  5. A. Akdogan1,
  6. S. Kiraz1,
  7. I. Ertenli1,
  8. U. Kalyoncu1
  1. 1Department of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
  2. 2Service de Rhumatologie, Maître de Conférence Universitaire - Praticien Hospitalier Université Pierre et Marie Curie Hôpital Pitié-Salpétrière, Paris, France


Background Recently, a EULAR (European League Against Rheumatism) working group developed the PsA impact of disease (PsAID) questionnaire which is a patient-derived composite index which assesses pain, skin problems, fatigue, work and/or leisure activities, functional capacity, uncomfortable feelings, sleep problems, anxiety-fear and uncertainty, coping, distress and/or embarrassment, social participation, and depression1. However this questionnaire has not yet been validated in other cohorts.

Objectives To validate the PsAID questionnaire in terms of correlation to other outcome measures in routine practice.

Methods Between January-December 2013, PsA patients on anti-TNF treatment were included in the HURBIO (Hacettepe University Rheumatology Biologic Registry) pragmatic observational study. Data collection comprised PsAID, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Dermatology Life Quality Index (DLQI), Health Assessment Questionnaire (HAQ), patient global Visual Analogue Scale (VAS), tender/swollen joints counts and DAS28. Non-parametric correlations between the PSAID score and the other outcome measures were assessed cross-sectionally. Feasibility was assessed by % missing data.

Results 111 patients were assessed: females 70%, mean age 44±12 years, mean disease duration 10.3±7,6 years, median anti-TNF treatment duration 16 (0- 100) months. There was a good correlation between PsAID and BASDAI (r=0.71), BASFI (r=0.72), HAQ (r=0.60), DLQI (r=0.47), and patient global VAS (r=0.59), and as expected correlations were moderate versus DAS28CRP (r=0.55), swollen joint count (r=0.25), and tender joint count (r=0.39). There was no correlation vs ESR or CRP level. Missing data in the 12 questions of the PsAID was unfrequent: 0.5%.

Conclusions PsAID is a recently developed patient reported outcome measure for PsA. In this study we showed that PsAID correlates with other composite indices for patients with PsA treated by anti-TNF. Furthermore the PsAID questionnaire was easy to fill in for the patient indicating good acceptability in a non-Western culture.


  1. Gossec, Laure, de Wit, Maarten, Balanescu, Andra, Balint, Peter V., Bekes, Gabor, Braun, Juergen, et al; Patient-Perceived Impact of Psoriatic Arthritis Is Due to Pain and Fatigue, but Also to Psychological Aspects – the Psa Impact of Disease Study. [abstract]. Arthritis Rheum 2011;63(Suppl 10):1296

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3915

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.